Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its cystic fibrosis focus into endocrine disease treatments. The deal could add up to $5 billion in annual revenue through approved drug Palsonify and pipeline candidate Atumelnant. While Vertex's stock initially fell post-announcement, the author suggests it could be a solid long-term buy given management's track record and enhanced growth prospects, despite the 29x trailing earnings valuation.